Nicorandil in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis

Table 2 Analysis of individual major adverse cardiovascular events demonstrating the safety of the nicorandil group

Outcome	Number of studies	Effect sizes		Heterogeneity
		RR (95%CI)	P value	Tau2	I2 (%)
VT/VF	15	0.51 (0.39-0.66)	< 0.01	0.01	0
Death	13	0.62 (0.33-1.15)	0.13	0	0
Myocardial infarction	6	0.79 (0.28-2.23)	0.66	0	0
TVR	5	0.60 (0.10-3.63)	0.58	0.87	25
Congestive heart failure	4	0.36 (0.20-0.66)	< 0.01	< 0.0001	0
Pericardial effusion	3	0.45 (0.17-1.21)	0.12	0.27	34
Chest pain	3	0.64 (0.31-1.33)	0.24	0.23	59
Acute stent thrombosis	2	0.65 (0.08-5.12)	0.69	0	0
Stroke	2	0.67 (0.08-5.35)	0.7	0	0
Heart failure	2	0.55 (0.25-1.22)	0.14	0	0
Angina	2	0.25 (0.11-0.59)	< 0.01	0	0
Postoperative hypotension	2	0.52 (0.15-1.81)	0.31	0	0
Cardiogenic shock	1	1.00 (0.06-15.43)	-	-	-
Intraoperative hypotension	1	0.13 (0.03-0.55)	-	-	-

RR: Risk ratio; CI: Confidence interval; VT: Ventricular tachycardia; VF: Ventricular fibrillation; TVR: Target vessel revascularization.